Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Assessment scales of the study population

From: The effect of concomitant fibromyalgia in HIV infected patients receiving antiretroviral therapy: a prospective cross-sectional study

Assessment scales Total of patients
n = 225 (%)
With FMS
n = 45 (%20)
Without FMS
n = 180 (%80)
p* values
FIQ 35.68 ± 22.72 58.53 ± 19.58 29.97 ± 19.69 0.001
BDI 16.41 ± 12.63 26.33 ± 14.51 13.93 ± 10.81 0.001
PSQI 6.16 ± 3.94 8.67 ± 3.87 5.53 ± 3.71 0.001
FSS 4.09 ± 1.82 5.49 ± 1.14 3.75 ± 1.79 0.001
SF-36
 Physical function (PF) 80.33 ± 27.68 52.00 ± 34.48 87.42 ± 20.36 0.001
 Physical role (PR) 64.67 ± 39.27 36.67 ± 39.02 71.67 ± 36.17 0.001
 Emotional role (ER) 58.67 ± 40.77 22.22 ± 31.78 67.77 ± 37.61 0.001
 Vitality (V) 56.53 ± 25.00 32.67 ± 19.96 62.50 ± 22.47 0.001
 Mental health (MH) 56.53 ± 22.81 44.27 ± 16.87 59.60 ± 23.11 0.001
 Social function (SF) 69.37 ± 26.47 50.83 ± 27.49 74.00 ± 24.14 0.001
 Bodily pain (BP) 70.03 ± 24.17 49.50 ± 27.84 75.17 ± 20.20 0.001
 General health (GH) 55.07 ± 25.69 33.00 ± 23.34 60.58 ± 23.21 0.001
  1. FIQ Fibromyalgia Impact Questionnaire, BDI Beck Depression Inventory, PSQI Pittsburgh Sleep Quality Index, FSS Fatigue Severity Scale, SF-36 Short- Form 36
  2. * p < 0.05 was considered significant